Please wait while the formulary information is being retrieved.
SYMPROIC (naldemedine tosylate)
- Opioid-induced constipation
0.2 mg tablet
- 1 tablet (0.2 mg) by oral route once daily
Opioid-induced constipation
- 1 tablet (0.2 mg) by oral route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Gastrointestinal obstruction
- Gastrointestinal perforation
Contraindicated
- None
Severe
Moderate
- None
SYMPROIC (naldemedine tosylate)
- Opioid-induced constipation
- None
- Acute abdominal pain
- Diarrhea
- Gastroenteritis
- Nausea
More Frequent
Severe
Less Severe
- None
- Opioid withdrawal symptoms
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Bronchospastic pulmonary disease
Less Severe
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Naldemedine
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Naldemedine
- Severity Level:
2
- Additional Notes: Crosses placenta, neonatal opioid withdrawal syndrome may occur
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Naldemedine
Insuff data available; if stopped, may resume bf 3 days later
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data available; if stopped, may resume bf 3 days later |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Opioid-induced constipation | |
| K59.09 | Other constipation |
| 0-9 | A-Z |
|---|---|
| K59.09 | Other constipation |
Formulary Reference Tool